

Phase 1 clinical trial of CKD-702, bispecific antibody, in NSCLC

Chong Kun Dang pharmaceutical Corp.



| ONCOLOGY | Phase 1 |
|---------------------------|--|
| Product Type | Bispecific antibody |
| Indication | Non small cell lung cancer (NSCLC) |
| Target | EGFR (Epidermal growth factor receptor) and cMET (Mesenchymal-epithelial transition factor) |
| MoA (Mechanism of Action) | <ul style="list-style-type: none"> • Binds to EGFR/cMET and inhibits downstream signaling pathways • Induces internalization and degradation • ADCC |
| Competitiveness | <ul style="list-style-type: none"> • Strong efficacy as a single agent in in vitro/vivo. • Enabling a biomarker-driven clinical design based on preclinical data. • Better safety profile (Infusion-related reaction) compared to competitor. |
| Development Stage | Phase 1, Part2 (POC studies for efficacy) |
| Route of Administration | Intravenous (iv) |